A detailed history of Callan Capital, LLC transactions in Pfizer Inc stock. As of the latest transaction made, Callan Capital, LLC holds 17,845 shares of PFE stock, worth $490,023. This represents 0.04% of its overall portfolio holdings.

Number of Shares
17,845
Previous 17,845 -0.0%
Holding current value
$490,023
Previous $499,000 -0.0%
% of portfolio
0.04%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$25.26 - $29.6 $64,438 - $75,509
2,551 Added 16.68%
17,845 $499,000
Q1 2024

Oct 22, 2024

SELL
$25.89 - $29.73 $66,045 - $75,841
-2,551 Reduced 14.3%
15,294 $424,000
Q1 2024

May 03, 2024

BUY
$25.89 - $29.73 $96,259 - $110,536
3,718 Added 32.12%
15,294 $424,000
Q4 2023

Feb 02, 2024

BUY
$26.13 - $33.94 $24,353 - $31,632
932 Added 8.76%
11,576 $333,000
Q3 2023

Nov 06, 2023

SELL
$32.09 - $37.51 $134,104 - $156,754
-4,179 Reduced 28.19%
10,644 $353,000
Q2 2023

Aug 04, 2023

BUY
$36.12 - $41.79 $4,767 - $5,516
132 Added 0.9%
14,823 $543,000
Q1 2023

Jun 13, 2023

SELL
$39.39 - $51.28 $126,717 - $164,967
-3,217 Reduced 17.96%
14,691 $599,000
Q1 2023

May 08, 2023

SELL
$39.39 - $51.28 $126,717 - $164,967
-3,217 Reduced 17.96%
14,691 $599,000
Q4 2022

Jun 13, 2023

BUY
$41.75 - $54.5 $134,309 - $175,326
3,217 Added 21.9%
17,908 $917,000
Q4 2022

Feb 13, 2023

BUY
$41.75 - $54.5 $110,387 - $144,098
2,644 Added 17.32%
17,908 $917,000
Q3 2022

Nov 14, 2022

BUY
$43.76 - $53.42 $242,474 - $296,000
5,541 Added 56.99%
15,264 $668,000
Q2 2022

Aug 15, 2022

BUY
$46.53 - $55.17 $229,439 - $272,043
4,931 Added 102.9%
9,723 $510,000
Q1 2022

May 10, 2022

BUY
$45.75 - $56.69 $12,123 - $15,022
265 Added 5.85%
4,792 $248,000
Q4 2021

Jan 21, 2022

BUY
$41.32 - $61.25 $187,055 - $277,278
4,527 New
4,527 $267,000

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $154B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Callan Capital, LLC Portfolio

Follow Callan Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Callan Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Callan Capital, LLC with notifications on news.